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Context: Lipoid congenital adrenal hyperplasia is a severe disorder
of adrenal and gonadal steroidogenesis caused by mutations in the
steroidogenic acute regulatory protein (StAR). Affected children typ-
ically present with life-threatening adrenal insufficiency in early in-
fancy due to a failure of glucocorticoid (cortisol) andmineralocorticoid
(aldosterone) biosynthesis, and 46,XY genetic males have complete
lack of androgenization and appear phenotypically female due to
impaired testicular androgen secretion in utero.
Objective: The objective of this study was to investigate whether
nonclassic forms of this condition exist.
Patients and Methods: Sequence analysis of the gene encoding
StAR was undertaken in three children from two families who pre-
sented with primary adrenal insufficiency at 2–4 yr of age; the males
had normal genital development. Identified mutants were tested in a
series of biochemical assays.
Results: DNA sequencing identified homozygous StAR mutations
Val187Met and Arg188Cys in these two families. Functional studies
of StAR activity in cells and in vitro and cholesterol-binding assays
showed these mutants retained 20% of wild-type activity.
Conclusions: These patients define a new disorder, nonclassic lipoid
congenital adrenal hyperplasia, and represent a new cause of non-
autoimmune Addison disease (primary adrenal failure). (J Clin En-
docrinol Metab 91: 4781–4785, 2006)
LIPOID CONGENITAL ADRENAL hyperplasia (CAH)(OMIM no. 201710), the most severe form of adrenal
hyperplasia, significantly impairs adrenal and gonadal ste-
roidogenesis by a defect in the conversion of cholesterol to
pregnenolone (1). Affected infants experience salt loss from
impaired mineralocorticoid and glucocorticoid synthesis,
but hormonal replacement therapy permits long-term sur-
vival (2). Because the fetal testis is affected, 46,XY genetic
males fail to produce testosterone and are born with female
external genitalia. The defect in lipoid CAH is primarily in
the steroidogenic acute regulatory protein (StAR) (3, 4),
which facilitates the entry of cholesterol into mitochondria,
where it becomes the substrate for the cholesterol side-chain
cleavage enzyme, P450scc (1, 5). Unlike abnormalities in
StAR, which is not expressed in placenta, defects in P450scc
will also disrupt placental progesterone synthesis, presum-
ably interrupting pregnancy, although rare mutations in
P450scc have been reported in children with adrenal failure
(6–9).
In most steroidogenic disorders, such as steroid 21-
hydroxylase deficiency, a spectrum of clinical findings re-
sults from different missense mutations. However, in lipoid
CAH, the clinical findings are remarkably similar; all indi-
viduals reported to date have had female external genitalia
irrespective of chromosomal sex and have had evidence of
salt loss in the first year of life, usually within the first 2
months (3, 4, 10–13).
We report three children from two families who have a
novel, mild form of lipoid CAH with their initial clinical
manifestations at 2–4 yr andnormal development of themale
genitalia in 46,XY individuals. This new disorder, termed
nonclassic lipoid CAH, illustrates that the clinical presenta-
tions of steroidogenic disorders can vary substantially from
their classic descriptions and identifies a new form of non-
autoimmune Addison disease (primary adrenal failure).
Patients and Methods
Case histories
Patient 1, a Pakistani (Gujakhan) 46,XX phenotypic female, had an
uneventful infancy, experienced fever and vomiting at 2 yr of age, and
was hypoglycemic during a viral illness at 4 yr. Progressive hyperpig-
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mentation prompted referral at 4.5 yr. Basal cortisol was undetectable
(1.0 g/dl), ACTH was elevated (1250 pg/ml), and cortisol did not
respond to stimulation with cosyntropin (Table 1). Plasma renin activity
(PRA) was mildly elevated (5.3 ng/ml/h; normal range, 0.3–3.9), but
sodium (138 mEq/liter), potassium (4.2 mEq/liter), and aldosterone
(15.5 ng/dl, normal range 4–31) were normal. She has remained well on
hydrocortisone replacement therapy (11–13 mg/m2/d), with normal
electrolytes and PRA (1.1–2.9 ng/ml/h).
Patients 2 and 3, Pakistani (Memon) 46,XY brothers from a consan-
guineous family, were born after uneventful pregnancies and had nor-
mal male genitalia with descended testes. The older boy developed
hyperpigmentation at 1.5 yr; investigation at 2.2 yr of age revealed low
basal cortisol (6.2 g/dl), elevated ACTH (1250 pg/ml), and no cor-
tisol response to cosyntropin stimulation, indicating compensated pri-
mary adrenal failure (Table 1). PRA was mildly elevated (5.4 ng/ml/h),
and aldosterone was at the lower range of normal (6.7 ng/dl). The
younger brother also became progressively pigmented. At 2.8 yr of age,
his cortisol (11.3 g/dl), aldosterone (12.4 ng/dl), and electrolytes were
normal, but his ACTH (1250 pg/ml) and PRA (20.2 ng/dl) were
elevated, and cortisol did not respond to cosyntropin. Computed to-
mography (CT) scans did not show adrenal enlargement. Both brothers
responded to replacement therapy with 9-fludrocortisone and
hydrocortisone.
Sequence analysis, mutagenesis, transfection, and
steroid measurement
DNA was extracted from blood leukocytes with institutional review
board approval. The seven exons of the human StAR gene were am-
plified by PCR and sequenced as described (11, 14). PCR-based site-
directed mutagenesis was used to recreate the mutations found in the
patients’ DNA in a full-length StAR cDNA expression vector (15), and
the resulting plasmids were sequenced to ensure accuracy. Using Li-
pofectamine (Invitrogen, Carlsbad, CA), nonsteroidogenic monkey kid-
ney COS-1 cells were cotransfected at 50–80% confluence with a StAR
expression vector and the F2 plasmid expressing a fusion protein of the
cholesterol side-chain cleavage system (H2N-P450scc-adrenodoxin re-
ductase-adrenodoxin-COOH) (16). Culture media were immunoas-
sayed for pregnenolone 48 h later.
Biochemical assays
The modifications of the pTWIN1 intein vector (New England Bio-
labs, Beverly,MA) for bacterial expression ofwild-type andmutantN-62
StAR, the preparation and quantitation of proteins, the steroidogenic
assays with isolated MA-10 cell mitochondria, and the assays of cho-
lesterol binding were performed as described previously (17), except
that nickel-nitrilotriacetic acid chromatography was added after the
chitin-binding column for the Val187Met mutant.
Structural modeling of missense mutants
Our computational model of human wild-type N-62 StAR (17, 18) was
modified by introducing missense mutations using the Swiss-Model pro-
gram (http://expasy.ch/spdbv/). Energy minimization was performed
with Amber 7 (http://amber.scripps.edu) (University of California, San
Francisco, Computer Graphics Laboratory). The resulting models were
checked with WHAT IF (http://swift.cmbi.kun.nl/WIWWWI/), and im-
ages were generated with Chimera (http://www.cgl.ucsf.edu/chimera).
Results
Mutation analysis
The clinical findings of compensated glucocorticoid and
mineralocorticoid deficiency in the presence of apparently
normal fetal testicular steroidogenesis suggested an abnor-
mality in a gene affecting adrenal function, but sequencing
of the ACTH receptor (MC2R), DAX1 (AHC, NR0B1), and
SF1 (steroidogenic factor 1, NR5A1) was normal. However,
the gene for StAR contained the homozygous mutation
Val187Met in patient 1 and the homozygous mutation
Arg188Cys in patients 2 and 3 (Fig. 1A). These residues are
highly conserved among vertebrate species (Fig. 1B). The
parents were heterozygous, and these mutations were not
detected in 200 control Pakistani alleles, indicating these
were functional mutations and not polymorphisms.
Structural modeling of missense mutations
To visualize the effects of these mutations, we used a
validated computational model of human StAR, showing
that Val187 and Arg188 lie in sheet 6, which contributes to
the sterol-binding pocket (17, 18) (Fig. 1C). Arg188 forms a
salt bridge with Glu169, coordinating with the 3OH group
of cholesterol to facilitate its binding (Fig. 1D). Mutation of
Glu169 to Gly or Lys causes lipoid CAH (4), confirming the
essential role of this residue, but the folding of the Glu169Gly
mutant is not as greatly disturbed as other severe mutants
(19). The adjacent Val187 residue does not have an obvious
function, but the modeling shows that its mutation to Met
should inhibit cholesterol binding sterically.
TABLE 1. Clinical and biochemical characteristics of patients with nonclassic lipoid CAH
Val187Met Arg188Cys
Normal range
Patient 1 Patient 2 Patient 3
Age at investigation (yr) 4.5 2.2 2.8
Presentation Hypoglycemia,
pigmentation
Pigmentation Pigmentation
Adrenal imaging Normal US Normal CT Normal CT
ACTH (pg/ml) 1250 1250 1250 10–50
Cortisol
Basal (g/dl) 1.0 6.2 11.3 5–15
Peak (g/dl) 1.0 5.6 10.5 20
PRA (ng/ml/h) 5.3 5.4 20.2 0.3–3.9
Aldosterone (ng/dl) 15.5 6.7 12.4 4–31
Treatment Hydrocortisone Hydrocortisone,
fludrocortisone
Hydrocortisone,
fludrocortisone
Conversion to Systeme International units: ACTH, picograms per milliliter 0.22 for picomoles per liter; cortisol, micrograms per deciliter
27.6 for nanomoles per liter; PRA, nanograms per milliliter per hour  0.77 for picomoles per milliliter per hour; aldosterone, nanograms per
deciliter  27.7 for picomoles per liter. US, Ultrasound scan.
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Functional analysis
StAR increases the flow of cholesterol from the outer mi-
tochondrial membrane (OMM) to the inner mitochondrial
membrane (IMM), where it is converted to pregnenolone to
initiate steroidogenesis. The activity of StAR mutants is typ-
ically assayed by transfecting nonsteroidogenic cells with
vectors expressing the cholesterol side-chain cleavage en-
zyme and StAR and measuring the amount of pregnenolone
produced. Use of a null StAR vector provides a negative
control, whereas addition of 22R-hydroxycholesterol (22R-
OH), which bypasses the action of StAR, provides a positive
control (3, 4, 13, 15). We cotransfected COS-1 cells with a
vector expressing the F2 fusion of the cholesterol side-chain
cleavage enzyme systemandwith a series of StAR expression
vectors and assayed pregnenolone (Fig. 2A). The lipo-
fectamine transfection protocol used here is more efficient
than the calcium phosphate procedure used in a previous
report (13), resulting in greater production of pregnenolone.
In the absence of StAR, the F2 enzyme exhibits a low level of
StAR-independent steroidogenesis (4, 16) at 10.7  1.7 ng
pregnenolone/ml culture medium. In the presence of 22R-
OH, cells expressing F2 made 321.7 57.4 ng/ml, indicating
the maximal level of steroidogenesis achievable under these
conditions. Using their endogenous cellular cholesterol as
substrate, cells cotransfected with F2, and wild-type StAR
generated 105.2  11.7 ng/ml. In contrast, the Val187Met
mutant generated 31.1  6.9 ng/ml, and the Arg188Cys
mutant generated 23.5  5.0 ng/ml. Thus, when the back-
ground of StAR-independent steroidogenesis is subtracted,
the Val187Met and Arg188Cys mutants have 21.6 and 13.6%
of wild-type activity, respectively; the activities of the two
mutants were significantly different (P  0.03) by a paired
two-tailed Student’s t test.
Biochemical analyses
To explore the mechanism by which these mutants retain
partial activity, we expressed each StAR protein in bacteria
using a self-splicing bacterial intein system. We purified
these proteins to homogeneity and tested their activities in
two cell-free systems. First, as an independent assay of the
capacity to induce steroidogenesis, we added each StAR
protein to mitochondria isolated from steroidogenic mouse
Leydig MA-10 cells and measured pregnenolone produced
from endogenous mitochondrial cholesterol (Fig. 2B). Wild-
type N-62 StAR elicited five times more steroidogenesis than
did buffer or the wholly inactive StAR mutant Met144Arg
(13, 17). After subtracting the buffer control, the Val187Met
and Arg188Cys mutants elicited 28.6 and 17.7% of wild-type
activity, respectively; this difference between the two mu-
tants was statistically significant (P  0.005) by a paired
two-tailed Student’s t test. Second,we found that the reduced
activity of these mutants was associated with reduced cho-
lesterol-binding capacity (Fig. 2C). Wild-type N-62 StAR
could bind either [14C]cholesterol (not shown) or fluorescent
nitrobenzoxadiazol (NBD) cholesterol, indicating that the
NBD group did not affect binding (17). The cholesterol-bind-
ing capacity of the Val187Met mutant was 25.5% of control,
and the capacity of the Arg188Cys mutant was 21.0% of the
capacity of the wild-type N-62 StAR. Thus, both mutants
retained partial cholesterol-binding capacity and partial ac-
tivity to induce steroidogenesis.
Discussion
StARmediates the rapid actions of ACTH and angiotensin
II on the adrenal and of LH on the gonad, permitting very
rapid rises in the circulating concentrations of steroids in
response to acute physiological stimuli. StAR elicits this ac-
tion by facilitating rapid movement of cholesterol from the
OMMto the IMM,where it is converted to pregnenolone. The
mechanism by which StAR moves cholesterol from OMM to
IMM is only partially understood. StAR acts exclusively on
the OMM (15, 20), where it undergoes acid-induced confor-
mational changes apparently induced by protonated OMM
phospholipids (17, 21, 22). StAR has a sterol-binding pocket
that accommodates one cholesterol molecule (17, 18), but
each molecule of StAR can mobilize approximately 400 mol-
FIG. 1. Mutation analysis. A, DNA sequencing: top,
wild-type control; middle, patient 1 with the
Val187Met mutation; bottom, patient 2 with the
Arg188Cys mutation. B, Alignment of the sequences of
residues 180–197 of the human, rat, mouse, sheep,
chicken, and zebrafish StARproteins; residues 187 and
188 are highlighted. C, Ribbon diagram of N-62 StAR,
positioned to permit both Val187 and Arg188 to be
seen; the amino (N) and carboxy (C) termini are indi-
cated. D, Arg188 normally forms a hydrogen bond with
Glu169; changing Arg188 to Cys eliminates hydrogen
bonding with Glu169 and creates a weak hydrogen
bond with Thr167.
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ecules of cholesterol (23). Although StAR is required for acute
steroidogenic responses, low levels of StAR-independent ste-
roidogenesis (e.g. in the placenta) proceed in its absence (3,
4). The presence of StAR-independent steroidogenesis ex-
plains the pathophysiology of lipoid CAH by a two-hit
model (4). Mutations in StAR ablate the acute response (the
first hit), resulting in low circulating steroid levels and com-
pensatory increases in ACTH, angiotensin II, and LH. These
increased tropic hormones stimulate cellular uptake of LDL
cholesterol and increased de novo cholesterol biosynthesis,
leading to accumulation of cholesterol and cholesterol esters
in lipid droplets in steroidogenic cells, eventually destroying
all steroidogenic capacity (the second hit). The two-hit model
explains the unusual findings in lipoid CAH. Salt loss ap-
pears relatively late because fetal angiotensin II drive is min-
imal, so that the adrenal zona glomerulosa remains relatively
undamaged until after birth; 46,XX patients spontaneously
feminize in adolescence because the fetal ovary is steroido-
genically quiescent and first experiences tropic stimulation at
puberty. This model has been confirmed by clinical obser-
vations (14, 24) and by observations in StAR knockout mice
(25).
Most disease-causing StAR mutations are devoid of mea-
surable activity. Only three mutations causing lipoid CAH
have had measurable activity in a transfected COS-1 cell
assay equivalent to the one we employed. Ala218Val (6%
activity) and Leu275Pro (10% activity) were both found in a
46,XY phenotypic female infant with salt loss at 2–4 months
(4); hence, this very low level of StAR activity is insufficient
to influence phenotype. Met225Thr (29% residual activity)
was found in a minimally virilized (clitoromegaly, rugated
labia, mild posterior labial fusion) 46,XY female who first
experienced salt loss at 10months of age (10). The coexistence
of the severe Glu258Stop null mutant on this patient’s other
allele presumably accelerated the course of the second hit, so
that the net effect was more severe than would be predicted
for aMet225Thr homozygote (10). In contrast, the Val187Met
and Arg188Cys mutations described in the present study,
which retain approximately 20–25% of activity, were seen in
homozygously affected individuals, permitting clear assess-
ment of the phenotypic consequences of retaining this degree
of StAR activity. The activities of the Val187Metmutant were
slightly greater than those of the Arg188Cys mutant in all
three assays, but it is not clearwhether these differenceswere
clinically significant. Although the partial activity in vitro
correlates well with milder, later onset disease, the presen-
tation of lipoid CAH can vary substantially among homozy-
goteswithin a single ethnic group; for example, among seven
Saudi patients homozygous for Arg182His, the age of onset
of symptoms ranged from 1–14 months, despite this mutant
lacking detectable activity in vitro (13). The consequences of
these nonclassical mutations on gonadal function cannot be
assessed during childhood; long-term follow-up through pu-
berty into adult life will be needed to assess the eventual
impact of thesemutations on ovarian and testicular function.
Lipoid CAHhas been described inmost ethnic groups and
is common in Japan, Korea, and some isolated populations
(1, 3, 4, 10, 11, 13, 24, 26–28). In contrast to previous reports
of lipoid CAH, our patients presented late: patient 1, a 46,XX
female homozygous for Val187Met, presented at 4 yr of age,
FIG. 2. Activity of StAR mutants. A, Activity in intact cells. COS-1
cells were cotransfected with expression vectors for the cholesterol
side-chain cleavage system and the indicated StAR vector, and preg-
nenolone was measured 48 h later. Addition of the StAR-independent
substrate 22R-OH in the absence of StAR indicates the maximum
steroidogenic capacity of the cells. Data are the mean  SEM from six
transfections, each performed in triplicate. B, Activity on mitochon-
dria in vitro. Mitochondria were isolated from steroidogenic mouse
Leydig (testicular) MA-10 cells, the indicated human N-62 StAR pro-
teins were added, and pregnenolone synthesis from endogenous mi-
tochondrial cholesterol stores was measured. Data are mean  SEM
from three experiments, each performed in triplicate. C, Cholesterol-
binding capacities. Binding of various concentrations of fluorescent
NBD cholesterol by wild type (black solid line), Val187Met (gray
dotted line), and Arg188Cys (black dotted line) was measured with a
protein concentration of 1 M; control is buffer without protein (gray
solid line). Data are mean  SEM for three experiments, each per-
formed in triplicate.
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whereas patients 2 and 3, 46,XY phenotypic male siblings
homozygous for Arg188Cys, presented at 2–3 yr. These
unique clinical courses, which are consistent with the dem-
onstrated partial activity of each mutation, establish a new
entity, nonclassic lipoid CAH, showing that the clinical spec-
trum of StAR mutations is substantially broader than had
been appreciated previously. Nonclassic lipoid CAH is thus
a novel form of nonautoimmuneAddison disease, which can
present with or without salt loss. Other genetic bases of
Addison disease probably remain to be identified.
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